--- title: "Vericel Q1 earnings call highlights" type: "News" locale: "en" url: "https://longbridge.com/en/news/285800108.md" description: "Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, driven by strong growth in its MACI cartilage repair franchise and Burn Care business, along with anticipated NexoBrid procurement revenue from a new federal contract. CEO Nick Colangelo highlighted the company's outstanding financial and commercial results during the earnings call." datetime: "2026-05-09T06:49:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285800108.md) - [en](https://longbridge.com/en/news/285800108.md) - [zh-HK](https://longbridge.com/zh-HK/news/285800108.md) --- # Vericel Q1 earnings call highlights 5 medical stocks growing earnings by triple digits Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract. President and Chief Executive Officer Nick Colangelo said the company delivered "outstanding financial and commercial results across... ### Related Stocks - [VCEL.US](https://longbridge.com/en/quote/VCEL.US.md) ## Related News & Research - [Vericel Independent Director Paul Wotton Sells 35% Of Holding](https://longbridge.com/en/news/286543900.md) - [Assessing Vericel (VCEL) Valuation After Recent Share Price Weakness And Contrasting Growth Narratives](https://longbridge.com/en/news/285959566.md) - [Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News](https://longbridge.com/en/news/286251150.md) - [Vericel beats Q1 revenue on MACI, burn care growth, lifts 2026 sales outlook](https://longbridge.com/en/news/285545416.md) - [Vericel forecasts $326M-$336M 2026 revenue as BARDA-backed NexoBrid procurement begins in H2](https://longbridge.com/en/news/285660366.md)